Novogene(688315) 长城证券·2024-05-08 23:32Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [20]. Core Views - The company is advancing its global localization strategy, enhancing its regional service capabilities to provide more efficient and stable products and services to global clients [2]. - The company's revenue for 2023 is reported at 2,002 million yuan, reflecting a year-on-year growth of 4.0%, with projections for 2024-2026 showing significant growth rates of 12.4%, 15.3%, and 20.0% respectively [8]. - The company has introduced multiple new sequencing platforms, improving service capabilities and meeting the latest sequencing demands from customers [8]. Financial Summary - Revenue (in million yuan): - 2022: 1,926 - 2023: 2,002 - 2024E: 2,251 - 2025E: 2,595 - 2026E: 3,113 - Year-on-year growth rates: - 2022: 3.2% - 2023: 4.0% - 2024E: 12.4% - 2025E: 15.3% - 2026E: 20.0% [8]. - Net profit attributable to the parent company (in million yuan): - 2022: 177 - 2023: 178 - 2024E: 205 - 2025E: 240 - 2026E: 284 - Year-on-year growth rates for net profit: - 2022: -21.3% - 2023: 0.5% - 2024E: 15.2% - 2025E: 16.9% - 2026E: 18.6% [8]. Business Performance - The company's domestic business faced short-term pressure, while overseas operations showed robust growth, with revenue from mainland China at 1,012 million yuan, down 9.43% year-on-year, and revenue from Hong Kong, Macau, Taiwan, and overseas regions at 985 million yuan, up 22.06% year-on-year [8]. - The company is steadily implementing its global localization strategy, having established laboratories in various countries including China, the USA, the UK, Singapore, Germany, and Japan [8].